Zoledronic Acid to Prevent Bone Loss after Acute SCI

Project Type
Principal Investigator Name
Principal Investigator Email
Start Date:
End Date:
Participating Centers:
Target Population(s):
Project Website:
The primary objectives of this investigation are to 1) compare bone mineral density (BMD) at the hip, distal femur and proximal tibia in subjects receiving a single dose of intravenous ZA to control subjects and 2) observe the timing of metabolic indexes of bone formation and resorption within the first 12 months following SCI in subjects who receive ZA relative to control subjects.